An insulin growth factor receptor (IGF) antagonist for use in the treatment of breast cancer patients in combination with exemestane and everolimus, where the IGF receptor antagonist is an antibody against IGF-1 and IGF-2 and having heavy chain complementarity determining regions of SEQ ID NO: 11 (HCDR1), SEQ ID NO: 12 (HCDR2) and SEQ ID NO: 13 (HCDR3), and light chain determining regions of SEQ ID NO : 14 (LCDR1), SEQ ID NO: 15 (LCDR2) and SEQ ID NO: 16 (LCDR3), or an antibody that has heavy chain complementarity determining regions of SEQ ID NO: 21 (HCDR1), SEQ ID NO : 22 (HCDR2) and SEQ ID NO: 23 (HCDR3), and light chain determining regions of SEQ ID NO: 24 (LCDR1), SEQ ID NO: 25 (LCDR2), and SEQ ID NO: 26 (LCDR3), or an antibody having heavy chain complementarity determining regions of SEQ ID NO: 31 (HCDR1), SEQ ID NO: 32 (HCDR2) and SEQ ID NO: 33 (HCDR3), and ca determining regions light dena of SEQ ID NO: 34 (LCDR1), SEQ ID NO: 35 (LCDR2) and SEQ ID NO: 36 (LCDR3), or an antibody having a SEQ ID NO: 17 heavy chain variable region and a region SEQ ID NO: 18 light chain variable, or an antibody having a SEQ ID NO: 27 heavy chain variable region and a SEQ ID NO: 28 light chain variable region, or an antibody having a variable region heavy chain SEQ ID NO: 37 and a light chain variable region of SEQ ID NO: 38, or an antibody having a heavy chain variable region of SEQ ID NO: 41 and a light chain variable region of SEQ ID NO: 42, or an antibody having a SEQ ID NO: 43 heavy chain variable region and a SEQ ID NO: 44 light chain variable region, or an antibody having a SEQ ID NO: 19 heavy chain and a light chain of SEQ ID NO: 20, or an antibody that has a heavy chain of SEQ ID NO: 29 and a light chain of SEQ ID NO: 30, or an antibody that has It has a heavy chain of SEQ ID NO: 39 and a light chain of SEQ ID NO: 40.Un antagonista del receptor del factor de crecimiento insulínico (IGF) para su uso en el tratamiento de pacientes con cáncer de mama en combinación con exem
